Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program
Authors' conclusion
Tirzepatide significatively reduced HbA1c and body weight in Hispanic/Latino and non-Hispanic/Latino patients. Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and within the overall trial populations.
Study context
- Population
- Patients with T2D in the SURPASS-1 to −4 trials
- Participants
- 5,679 patients
- Comparison
- Tirzepatide 5, 10 or 15 mg vs placebo or active comparator (semaglutide 1 mg, insulin degludec, insulin glargine), in Hispanic/Latino and non-Hispanic/Latino patients
- Hispanic/Latinon = 2,895
- Primary endpoint
- Change in HbA1c and body weight from baseline
- Follow-up
- Week 40 (SURPASS-1 and −2) and week 52 (SURPASS-3 and −4)
Methodological detailsexploratory analysis
- Exploratory analysis
Primary result
As reported in the abstract
- Hispanic/Latino: Hemoglobin A1c (HbA1c) decrease range
- 1.9% to 2.7%
- non-Hispanic/Latino: HbA1c decrease range
- 1.7% to 2.5%
- Hispanic/Latino: body weight decrease range
- 5.3 kg to 12.4
- non-Hispanic/Latino: body weight decrease range
- 6.5 kg to 17.1 kg
- Decreases significant vs comparators across all trials
- P < .05
Safety
Treatment-emergent adverse events and hypoglycaemia
- TEAEs reported in similar proportions across subgroups, primarily gastrointestinal disorders
- Incidence of hypoglycemia was low
Original publication
Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program. J Clin Endocrinol Metab. Published 21 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →